Table 3.
Baseline and follow-up biomarkers in SLE-ILD/myositis cases versus controls
| Biomarker variables | Baseline testing | Follow-up testing | |||
|---|---|---|---|---|---|
| Controls N = 72 |
ILD and/or Myositis N = 14 |
Controls N = 72 |
ILD and/or Myositis N = 14 |
||
| Anti-Mi2α, N (%)a | 2 (2.8) | 0 (0.0) | 0 (0.0) | 1 (7.1) | |
| Anti-Mi2β, N (%)a | 0 (0.0) | 0 (0.0) | 1 (1.4) | 0 (0.0) | |
| Anti-TIF1γ, N (%)a | 0 (0.0) | 0 (0.0) | 1 (1.4) | 0 (0.0) | |
| Anti–PM/Scl-75, N (%)a | 2 (2.8) | 0 (0.0) | 3 (4.2) | 0 (0.0) | |
| Anti–PM/Scl-100, N (%)a | 2 (2.8) | 0 (0.0) | 2 (2.8) | 0 (0.0) | |
| Anti-Ku, N (%)a | 1 (1.4) | 3 (21.4) | 0 (0.0) | 3 (21.4) | |
| Anti-PL7, N (%)a | 1 (1.4) | 0 (0.0) | 2 (2.8) | 0 (0.0) | |
| Anti-Ro52/TRIM21, N (%)a | 15 (20.8) | 6 (42.9) | 14 (19.4) | 5 (35.7) | |
| Anti-HMGCR, positive, N (%)a | 0 (0.0) | 1 (7.1) | 0 (0.0) | 1 (7.1) | |
| Anti-NT5c1A/Mup4, N (%)a | 5 (6.9) | 1 (7.1) | 5 (6.9) | 1 (7.1) | |
| Anti–CENP-A, N (%)a | 5 (6.9) | 1 (7.1) | 4 (5.6) | 1 (7.1) | |
| Anti–CENP-B, N (%)a | 2 (2.8) | 2 (14.3) | 2 (2.8) | 0 (0.0) | |
| Anti-NOR90, N (%)a | 0 (0.0) | 1 (7.1) | 0 (0.0) | 1 (7.1) | |
| Anti-Scl70, N (%)a | 0 (0.0) | 0 (0.0) | 1 (1.4) | 0 (0.0) | |
| Anti-Th/To/hPOP1, N (%)a | 0 (0.0) | 0 (0.0) | 2 (2.8) | 0 (0.0) | |
| Anti-RNPC3 > 500 U/mL, N (%) | 21 (29.2) | 3 (21.4) | 23 (31.9) | 2 (14.3) | |
| Anti–TERF-1 > 500 U/mL, N (%) | 4 (5.6) | 1 (7.1) | 3 (4.2) | 2 (14.3) | |
| KL-6 >500 U/mL, N (%) | 21 (29.2) | 7 (50.0) | 14 (19.4) | 8 (61.5) | |
MDA5: melanoma differentiation-associated gene 5; NXP2: nuclear matrix protein-2; TIF1γ: transcriptional intermediary factor 1γ; SRP: signal recognition particle; HMGCR: hydroxymethylglutaryl CoA reductase; NT5C1A: cytosolic 5′-nucleotidase 1A/Mup44; CENP: centromere antigens-A, -B; Scl70: topoisomerase 1; NOR90: nucleolus-organizing regions-90; RNAP: RNA polymerase III; hPOP1: Th/To; TERF-1: telomeric repeat binding factor −1; KL-6: Krebs von den Lungen-6.
aMedium/high positive, ≥ 31 signal intensity.